• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Pharmacodynamic interference between rifampicin and isoniazid.

作者信息

Llorens J, Serrano R J, Sanchez R

出版信息

Chemotherapy. 1978;24(2):97-103. doi: 10.1159/000237767.

DOI:10.1159/000237767
PMID:620612
Abstract

This study includes 30 children below the age of 3 years, distributed in three groups of 10 children each. One group received 15 mg/kg/day of rifampicin (RAMP), the other received 15 mg/kg/day of isoniazid (INH) and the third received both drugs (RAMP + INH) at the same doses. Plasma levels of RAMP and INH were determined. At the same time, some hepatic function parameters were analyzed: bilirubin, transaminases, alkaline phosphatases and prothrombin. Plasma levels of INH administered alone show significantly higher levels on the 7th day with respect to the 1st day, thus demonstrating a marked tendency towards the accumulation of successive doses. Very significant differences exist between initial and final values of transaminases in the RAMP + INH group. There are no significant differences in the other two groups. These data suggest a hepatic overload when both drugs are simultaneously administered.

摘要

相似文献

1
Pharmacodynamic interference between rifampicin and isoniazid.
Chemotherapy. 1978;24(2):97-103. doi: 10.1159/000237767.
2
Effect of different oral doses of isoniazid-rifampicin in rats.不同口服剂量异烟肼-利福平对大鼠的影响。
Mol Cell Biochem. 2006 Sep;289(1-2):39-47. doi: 10.1007/s11010-006-9145-3. Epub 2006 Apr 1.
3
Pharmacokinetic and safety evaluation of the use of ciprofloxacin on an isoniazid-rifampicin regimen in rabbits.环丙沙星在利福平异烟肼方案中在兔体内的药代动力学和安全性评价。
Biopharm Drug Dispos. 2012 Dec;33(9):501-9. doi: 10.1002/bdd.1817. Epub 2012 Oct 25.
4
Pharmacological study of rifampicin after repeated high dosage during intermittent combined therapy. II. Bilirubin levels and other biochemical determinations.
Respiration. 1971;28:Suppl:17-28. doi: 10.1159/000194958.
5
The Australian rifampicin trial.澳大利亚利福平试验。
Med J Aust. 1971 Jul 10;2(2):85-94.
6
[The influence of rifampicin upon the metabolism of isoniazid (author's transl)].
Nouv Presse Med. 1978 Apr 15;7(15):1263-7.
7
Naringenin protects against isoniazid- and rifampicin-induced apoptosis in hepatic injury.柚皮素可预防异烟肼和利福平诱导的肝损伤中的细胞凋亡。
World J Gastroenterol. 2016 Nov 28;22(44):9775-9783. doi: 10.3748/wjg.v22.i44.9775.
8
Hepatoprotective activity of melittin on isoniazid- and rifampicin-induced liver injuries in male albino rats.蜂毒素对异烟肼和利福平致雄性白化大鼠肝损伤的保护作用。
BMC Pharmacol Toxicol. 2021 Jul 3;22(1):39. doi: 10.1186/s40360-021-00507-9.
9
Hepatoprotective effect of Anacyclus pyrethrum Linn. against antitubercular drug-induced hepatotoxicity in SD rats.刺苞术对SD大鼠抗结核药物诱导的肝毒性的保肝作用。
J Complement Integr Med. 2016 Sep 1;13(3):295-300. doi: 10.1515/jcim-2016-0001.
10
[Liver toxicity of combined rifampicin-isoniazid-ethambutol medication (author's transl)].利福平-异烟肼-乙胺丁醇联合用药的肝脏毒性(作者译)
Dtsch Med Wochenschr. 1974 May 31;99(22):1182 p. doi: 10.1055/s-0028-1107914.

引用本文的文献

1
Adequacy of the 10 mg/kg Daily Dose of Antituberculosis Drug Isoniazid in Infants under 6 Months of Age.6个月以下婴儿每日10mg/kg抗结核药物异烟肼剂量的充足性
Antibiotics (Basel). 2023 Jan 30;12(2):272. doi: 10.3390/antibiotics12020272.
2
Pharmacokinetics of isoniazid, rifampin, and pyrazinamide in children younger than two years of age with tuberculosis: evidence for implementation of revised World Health Organization recommendations.异烟肼、利福平、吡嗪酰胺在 2 岁以下儿童结核病患者中的药代动力学:实施世界卫生组织修订建议的证据。
Antimicrob Agents Chemother. 2011 Dec;55(12):5560-7. doi: 10.1128/AAC.05429-11. Epub 2011 Oct 3.
3
Clinical pharmacokinetics of the antituberculosis drugs.
抗结核药物的临床药代动力学。
Clin Pharmacokinet. 1984 Nov-Dec;9(6):511-44. doi: 10.2165/00003088-198409060-00003.